Cytosorbents (CTSO) Stock Price, News & Analysis

Company Overview

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

Key Stats

• Today's Range: $1.03 to $1.11
• 50-Day Range: $0.81 to $1.16
• 52-Week Range: $0.70 to $1.61
• Volume: 69,364 shs
• Average Volume: 147,537 shs
• Market Capitalization: $68.24 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.50
• Consensus Rating: Buy

Cytosorbents Stock Analysis - MarketRank™

Cytosorbents scored higher than 35% of companies evaluated by MarketBeat, and ranked 701st out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Cytosorbents has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Cytosorbents has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cytosorbents are expected to grow in the coming year, from ($0.30) to ($0.17) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cytosorbents is -3.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cytosorbents is -3.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cytosorbents has a P/B Ratio of 2.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

2.86% of the float of Cytosorbents has been sold short.

Short Interest Ratio / Days to Cover

Cytosorbents has a short interest ratio ("days to cover") of 14.6, which indicates bearish sentiment.

Change versus previous month

Short interest in Cytosorbents has recently decreased by 2.01%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cytosorbents does not currently pay a dividend.

Dividend Growth

Cytosorbents does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.86% of the float of Cytosorbents has been sold short.

Short Interest Ratio / Days to Cover

Cytosorbents has a short interest ratio ("days to cover") of 14.6, which indicates bearish sentiment.

Change versus previous month

Short interest in Cytosorbents has recently decreased by 2.01%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.85

News Sentiment

Cytosorbents has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Cytosorbents this week, compared to 2 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cytosorbents insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 6.60% of the stock of Cytosorbents is held by insiders.

Percentage Held by Institutions

Only 32.87% of the stock of Cytosorbents is held by institutions.

CTSO Stock Analysis - Frequently Asked Questions

How have CTSO shares performed this year?

Cytosorbents' stock was trading at $0.91 at the beginning of 2025. Since then, CTSO stock has increased by 19.8% and is now trading at $1.09.
View the best growth stocks for 2025 here.

How were Cytosorbents' earnings last quarter?

Cytosorbents Co. (NASDAQ:CTSO) announced its earnings results on Wednesday, May, 14th. The medical research company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.02. The medical research company earned $8.73 million during the quarter, compared to the consensus estimate of $9.01 million. Cytosorbents had a negative net margin of 49.47% and a negative trailing twelve-month return on equity of 118.54%.
Read the conference call transcript.

Who are Cytosorbents' major shareholders?

Cytosorbents' top institutional shareholders include Avenir Corp (8.06%), Skylands Capital LLC (4.80%), CM Management LLC (1.52%) and Sargent Investment Group LLC (1.32%). Insiders that own company stock include Phillip P Chan, Vincent Capponi, Alan D Sobel, Michael G Bator, Jiny Kim and Kathleen P Bloch.
View institutional ownership trends.

How do I buy shares of Cytosorbents?

Shares of CTSO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cytosorbents own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cytosorbents investors own include Cuisine Solutions (CUSI), InnerScope Hearing Technologies (INND), Gilead Sciences (GILD), Johnson & Johnson (JNJ), Corning (GLW), UnitedHealth Group (UNH) and DocuSign (DOCU).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 6/14/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:CTSO
• CIK: 1175151
• Web: www.cytosorbents.com
• Phone: (732) 329-8885
• Fax: 732-329-8650
• Employees: 220
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $5.50
• High Stock Price Target: $10.00
• Low Stock Price Target: $1.00
• Potential Upside/Downside: +404.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.28)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$28.51 million
• Net Margins: -49.47%
• Pretax Margin: -51.62%
• Return on Equity: -118.54%
• Return on Assets: -42.31%

Debt

• Debt-to-Equity Ratio: 1.06
• Current Ratio: 1.97
• Quick Ratio: 1.58

Sales & Book Value

• Annual Sales: $35.33 million
• Price / Sales: 1.93
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.52 per share
• Price / Book: 2.10

Miscellaneous

• Outstanding Shares: 62,610,000
• Free Float: 51,071,000
• Market Cap: $68.24 million
• Optionable: Optionable
• Beta: 1.05